ESMO 2019 | ILLUMINATE 101: Updates and implications on colorectal cancer

Hani Babiker • 18 Oct 2019

Colorectal Cancer Gastrointestinal Cancer IMO-2125 Ipilimumab Nivolumab

Hani Babiker, MD, The University of Arizona, Tucson, AZ, discusses updates from the ILLUMINATE 101 (NCT03052205) regarding the intratumoral treatment of solid tumors with IMO-2125 and the implications of results on colorectal cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Cemiplimab prospects: CRC, CSCC & HNSCC

Hani Babiker • 29 Nov 2018

A promising future for drug development in gastrointestinal cancer

Hani Babiker • 29 Nov 2018

Molecular target therapy in pancreatic and liver cancer

Hani Babiker • 18 Oct 2019

Current trials in colorectal cancer investigating panitumumab

Hani Babiker • 29 Nov 2018

Related Videos

EuropaColon survey of the unmet needs of metastatic colorectal cancer patients

Geoffrey Henning • 3 Mar 2017

Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions

Milind Javle • 1 Jul 2020

A promising future for drug development in gastrointestinal cancer

Hani Babiker • 29 Nov 2018

Treatment landscape for HCC

Arndt Vogel • 9 Nov 2018